Using KinetiSol™ Technology To Improve An Abandoned Prostate Cancer Medication

Prostate cancer remains a significant health concern, accounting for 10% of male cancer-related deaths in 2019. While initial treatment strategies focused on reducing testosterone and androgens, finding a definitive cure has proven challenging due to drug resistance and the development of new drugs. This case study highlights the potential of KinetiSol™ technology in revitalizing an abandoned prostate cancer medication.

Galeterone, a potential treatment for prostate cancer, was discontinued after a Phase III clinical trial showed it to be ineffective. The drug was reformulated using KinetiSol Solid Dispersion (KSD), resulting in a 2x increase in in vivo exposure. The challenges of galeterone, including low bioavailability and water solubility, were addressed by KinetiSol technology.

The study compared various formulations and found that KinetiSol outperformed spray-dried formulations in terms of dissolution area under the curve (AUC). Lowering the drug load in KinetiSol resulted in a 7.2x increase in dissolution AUC, suggesting its potential to improve treatment outcomes.

In vivo studies on rats showed that KinetiSol had a 2.15 times higher relative bioavailability compared to spray-dried formulations. The optimized particle morphology achieved through KinetiSol formulations also improved drug release. Review the case study and learn how KSD lowered the pill burden and demonstrated an improved therapeutic response.